The effect of beta-blockers in acute heart failure according to heart rate
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (HF) patients. We evaluated the prescribing status of BBs in patients with HF with reduced ejection fraction (HFrEF) at discharge according to the presence or not of bradycardia, and its effect on prognosis. Methods: Study data were obtained from a multicenter cohort of 3,200 patients hospitalized for HF. Patients were classified into four groups according to the presence of bradycardia and use of BBs at discharge. The primary outcome was the incidence of all-cause death during follow-up. Results: Of 1,584 patients with HFrEF, 281 patients died during follow-up (median 523 days, mean 578.5 ± 429.7 days). In patients with bradycardia, the all-cause death rate did not significantly differ according to the use of BBs, but in those patients without bradycardia, the incidence of all-cause death was significantly lower in the BBs group than the no BBs group. Among these four groups, patients with heart rate (HR) ≥ 60 beats/min with no BBs group had the lowest cumulative death-free survival rate. In addition, HR ≥ 60 beats/min with BBs use was independently associated with a 31% reduced risk of all-cause death in patients with HFrEF. Conclusions: BBs had a beneficial effect on clinical prognosis only in those HFrEF patients without bradycardia. Therefore, BBs should be given by clinicians to HF patients without bradycardia to improve their clinical outcomes.
Abstract
Background/Aims: Beta-blockers (BBs) have been shown to improve clinical outcomes in heart failure (HF) patients. We evaluated the prescribing status of BBs in patients with HF with reduced ejection fraction (HFrEF) at discharge according to the presence or not of bradycardia, and its effect on prognosis. Methods: Study data were obtained from a multicenter cohort of 3,200 patients hospitalized for HF. Patients were classified into four groups according to the presence of bradycardia and use of BBs at discharge. The primary outcome was the incidence of all-cause death during follow-up. Results: Of 1,584 patients with HFrEF, 281 patients died during follow-up (median 523 days, mean 578.5 ± 429.7 days). In patients with bradycardia, the all-cause death rate did not significantly differ according to the use of BBs, but in those patients without bradycardia, the incidence of all-cause death was significantly lower in the BBs group than the no BBs group. Among these four groups, patients with heart rate (HR) ≥ 60 beats/min with no BBs group had the lowest cumulative death-free survival rate. In addition, HR ≥ 60 beats/min with BBs use was independently associated with a 31% reduced risk of all-cause death in patients with HFrEF. Conclusions: BBs had a beneficial effect on clinical prognosis only in those HFrEF patients without bradycardia. Therefore, BBs should be given by clinicians to HF patients without bradycardia to improve their clinical outcomes.
참고문헌 (22)
- Kannel WB, "Heart rate and cardiovascular mortality : the Framingham Study", Am Heart J, 113, pp.1489~1494 (1987)
- Lechat P, "Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial", Circulation, 103, pp.1428~1433 (2001)
- Pocock SJ, "Predictors of mortality and morbidity in patients with chronic heart failure", Eur Heart J, 27, pp.65~75 (2006)
- Ponikowski P, "2016 ESC guide lines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)developed with the special contribution of the Heart Failure Association(HFA)of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
- Yancy CW, "2017 ACC", AHA, AHA guideline for the management of heart failure : a report of the American College of Cardiology, pp.American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, J Am Coll Cardiol[DOI]
- McAlister FA, "Meta-analysis : beta-blocker dose, heart rate reduction, and death in patients with heart failure", Ann Intern Med, 150, pp.784~794 (2009)
- Gilstrap LG, "Reasons for guideline nonadherence at heart failure discharge", J Am Heart Assoc, 7, pp.e008789~ (2018)
- Teng TK, "Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry : a cohort study", Lancet Glob Health, 6, pp.e1008~e1018 (2018)
- Mahmood SS, "The epidemiology of congestive heart failure : the Framingham Heart Study perspective", Glob Heart, 8, pp.77~82 (2013)
- Kim HJ, "Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease : propensity score matching analysis", Circ J, 84, pp.83~90 (2019)
- Kusumoto FM, "2018ACC", AHA, American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, pp.Circulation, 2019[DOI]
- Cullington D, "Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?", Eur J Heart Fail, 14, pp.737~747 (2012)
- Kotecha D, "Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure", J Am Coll Cardiol, 69, pp.2885~2896 (2017)
- Packer M, "Effect of carvedilol on survival in severe chronic heart failure", N Engl J Med, 344, pp.1651~1658 (2001)
- CIBIS Investigators and Committees, "A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS)", Circulation, 90, pp.1765~1773 (1994)
- "Effect of metoprolol CR", XL in chronic heart failure: Metoprolol CR, Lancet, pp.1999, 353[DOI]
- Fiuzat M, "Heart rate or beta-blocker dose? : association with outcomes in ambulatory heart failure patients with systolic dysfunction : results from the HF-ACTION trial", JACC Heart Fail, 4, pp.109~115 (2016)
- Swedberg K, "Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure : is there an influence of beta-blocker dose? : findings from the SHIFT(Systolic Heart failure treatment with the I(f)inhibitor ivabradine Trial)study", J Am Coll Cardiol, 59, pp.1938~1945 (2012)
- Ibrahim NE, "Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction", Eur Heart J Cardiovasc Pharmacother, 5, pp.3~11 (2019)
- Anand IS, "C-reactive protein in heart failure : prognostic value and the effect of valsartan", Circulation, 112, pp.1428~1434 (2005)
- Verma S, "Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein", Circulation, 105, pp.1890~1896 (2002)
- Pasceri V, "Direct proinflammatory effect of C-reactive protein on human endothelial cells", Circulation, 102, pp.2165~2168 (2000)